Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$4.4 - $7.86 $12.9 Million - $23.1 Million
-2,936,063 Closed
0 $0
Q2 2024

Jul 26, 2024

SELL
$4.76 - $12.79 $14.8 Million - $39.7 Million
-3,104,413 Reduced 51.39%
2,936,063 $14.3 Million
Q1 2024

Apr 18, 2024

SELL
$10.81 - $17.96 $10.6 Million - $17.7 Million
-984,640 Reduced 14.02%
6,040,476 $80.2 Million
Q4 2023

Jan 17, 2024

BUY
$8.84 - $18.7 $16.1 Million - $34.1 Million
1,824,549 Added 35.08%
7,025,116 $97.9 Million
Q3 2023

Oct 18, 2023

BUY
$11.42 - $20.82 $567,756 - $1.04 Million
49,716 Added 0.97%
5,200,567 $69 Million
Q2 2023

Jul 10, 2023

BUY
$13.34 - $19.9 $8.92 Million - $13.3 Million
668,760 Added 14.92%
5,150,851 $96.6 Million
Q1 2023

Apr 17, 2023

BUY
$14.3 - $24.01 $1.66 Million - $2.79 Million
116,261 Added 2.66%
4,482,091 $64.6 Million
Q4 2022

Jan 24, 2023

BUY
$17.85 - $40.7 $17.3 Million - $39.6 Million
971,971 Added 28.64%
4,365,830 $0
Q3 2022

Oct 17, 2022

BUY
$15.63 - $41.49 $21.3 Million - $56.4 Million
1,359,735 Added 66.85%
3,393,859 $117 Million
Q2 2022

Jul 11, 2022

BUY
$11.14 - $23.17 $3.87 Million - $8.04 Million
347,179 Added 20.58%
2,034,124 $30.8 Million
Q1 2022

Apr 19, 2022

BUY
$20.92 - $39.36 $6.01 Million - $11.3 Million
287,400 Added 20.54%
1,686,945 $38.5 Million
Q4 2021

Jan 28, 2022

BUY
$31.94 - $54.82 $4.21 Million - $7.23 Million
131,840 Added 10.4%
1,399,545 $51.6 Million
Q3 2021

Nov 12, 2021

BUY
$46.0 - $73.99 $33.1 Million - $53.2 Million
719,316 Added 131.17%
1,267,705 $59.6 Million
Q2 2021

Aug 05, 2021

BUY
$31.92 - $60.25 $17.5 Million - $33 Million
548,389 New
548,389 $33 Million

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $378M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track Cathie Wood's Portfolio

Track Cathie Wood Portfolio

Follow Cathie Wood (Ark Investment Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.